170 related articles for article (PubMed ID: 36064602)
1. Targeting novel sites in DNA gyrase for development of anti-microbials.
Salman M; Sharma P; Kumar M; Ethayathulla AS; Kaur P
Brief Funct Genomics; 2023 Apr; 22(2):180-194. PubMed ID: 36064602
[TBL] [Abstract][Full Text] [Related]
2. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
[TBL] [Abstract][Full Text] [Related]
3. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents.
Khan T; Sankhe K; Suvarna V; Sherje A; Patel K; Dravyakar B
Biomed Pharmacother; 2018 Jul; 103():923-938. PubMed ID: 29710509
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
[TBL] [Abstract][Full Text] [Related]
5. Schematic-portfolio of potent anti-microbial scaffolds targeting DNA gyrase: Unlocking ways to overcome resistance.
Pakeeraiah K; Mal S; Mahapatra M; Mekap SK; Sahu PK; Paidesetty SK
Int J Biol Macromol; 2024 Jan; 256(Pt 2):128402. PubMed ID: 38035955
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in the discovery and development of DNA gyrase B inhibitors.
Barančoková M; Kikelj D; Ilaš J
Future Med Chem; 2018 May; 10(10):1207-1227. PubMed ID: 29787300
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
[TBL] [Abstract][Full Text] [Related]
8. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
[TBL] [Abstract][Full Text] [Related]
9. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.
Collins JA; Osheroff N
ACS Infect Dis; 2024 Apr; 10(4):1097-1115. PubMed ID: 38564341
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.
Gibson EG; Bax B; Chan PF; Osheroff N
ACS Infect Dis; 2019 Apr; 5(4):570-581. PubMed ID: 30757898
[TBL] [Abstract][Full Text] [Related]
11. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.
Tomašić T; Mašič LP
Curr Top Med Chem; 2014; 14(1):130-51. PubMed ID: 24236722
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in DNA gyrase-targeted antimicrobial agents.
Dighe SN; Collet TA
Eur J Med Chem; 2020 Aug; 199():112326. PubMed ID: 32460040
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
14. DNA Gyrase Is the Target for the Quinolone Drug Ciprofloxacin in Arabidopsis thaliana.
Evans-Roberts KM; Mitchenall LA; Wall MK; Leroux J; Mylne JS; Maxwell A
J Biol Chem; 2016 Feb; 291(7):3136-44. PubMed ID: 26663076
[TBL] [Abstract][Full Text] [Related]
15. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
[TBL] [Abstract][Full Text] [Related]
16. Structural and mechanistic analysis of ATPase inhibitors targeting mycobacterial DNA gyrase.
Henderson SR; Stevenson CEM; Malone B; Zholnerovych Y; Mitchenall LA; Pichowicz M; McGarry DH; Cooper IR; Charrier C; Salisbury AM; Lawson DM; Maxwell A
J Antimicrob Chemother; 2020 Oct; 75(10):2835-2842. PubMed ID: 32728686
[TBL] [Abstract][Full Text] [Related]
17. Dual Escherichia coli DNA Gyrase A and B Inhibitors with Antibacterial Activity.
Fois B; Skok Ž; Tomašič T; Ilaš J; Zidar N; Zega A; Peterlin Mašič L; Szili P; Draskovits G; Nyerges Á; Pál C; Kikelj D
ChemMedChem; 2020 Feb; 15(3):265-269. PubMed ID: 31721445
[TBL] [Abstract][Full Text] [Related]
18. Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance.
Gross CH; Parsons JD; Grossman TH; Charifson PS; Bellon S; Jernee J; Dwyer M; Chambers SP; Markland W; Botfield M; Raybuck SA
Antimicrob Agents Chemother; 2003 Mar; 47(3):1037-46. PubMed ID: 12604539
[TBL] [Abstract][Full Text] [Related]
19. Identification of an ethyl 5,6-dihydropyrazolo[1,5-c]quinazoline-1-carboxylate as a catalytic inhibitor of DNA gyrase.
Aguirre AL; Chheda PR; Lentz SRC; Held HA; Groves NP; Hiasa H; Kerns RJ
Bioorg Med Chem; 2020 May; 28(10):115439. PubMed ID: 32234278
[TBL] [Abstract][Full Text] [Related]
20. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
